ATC Group: N01BB Amides

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N01BB in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N01 Anesthetics
3 N01B Anesthetics, local
4 N01BB Amides

Group N01BB contents

Code Title
N01BB01 Bupivacaine
N01BB02 Lidocaine
N01BB03 Mepivacaine
N01BB04 Prilocaine
N01BB05 Butanilicaine
N01BB06 Cinchocaine
N01BB07 Etidocaine
N01BB08 Articaine
N01BB09 Ropivacaine
N01BB10 Levobupivacaine
N01BB20 Combinations
N01BB51 Bupivacaine, combinations
N01BB52 Lidocaine, combinations
N01BB53 Mepivacaine, combinations
N01BB54 Prilocaine, combinations
N01BB57 Etidocaine, combinations
N01BB58 Articaine, combinations
N01BB59

Active ingredients in N01BB

Active Ingredient

Articaine is a local anaesthetic of the amide type. Preclinical pharmacodynamic studies show that the mechanism of action of articaine is similar to that of other commonly used anaesthetics.

Bupivacaine is an amide-type, long-acting local anesthetic. Bupivicaine reversibly binds to specific sodium ion channels in the neuronal membrane, resulting in a decrease in the voltage-dependent membrane permeability to sodium ions and membrane stabilization; inhibition of depolarization and nerve impulse conduction; and a reversible loss of sensation.

Cinchocaine is a local anaesthetic agent and is suitable for surface or spinal anaesthesia and for relaxing sphincteric spasms. It is an anaesthetic of the amide type. It is more toxic than cocaine by local application but its local anaesthetic action is greater so it can be used in lower concentrations. Its action is more prolonged than lignocaine.

Levobupivacaine is a long acting local anaesthetic and analgesic. It blocks nerve conduction in sensory and motor nerves largely by interacting with voltage sensitive sodium channels on the cell membrane, but also potassium and calcium channels are blocked. In addition, levobupivacaine interferes with impulse transmission and conduction in other tissues where effects on the cardiovascular and central nervous systems are most important for the occurrence of clinical adverse reactions.

Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane.

Mepivacaine is an amide local anaesthetic. Mepivacaine has a rapid onset, a high potency of anaesthesia and a low toxicity.

Prilocaine is a toluidine derivative and intermediate-acting amino amide with local anesthetic property. Prilocaine binds to the intracellular surface of sodium channels which blocks the subsequent influx of sodium into the cell. Action potential propagation and never function is, therefore, prevented. This block is reversible and when the drug diffuses away from the cell, sodium channel function is restored and nerve propagation returns.

Ropivacaine is a long-acting amide-type local anaesthetic with both anaesthetic and analgesic effects. At high doses ropivacaine produces surgical anaesthesia, while at lower doses it produces sensory block with limited and non-progressive motor block.

Related product monographs

Document Type Information Source  
 BUPICAN Solution for injection MPI, Generic Health Products Regulatory Authority (ZA)
 CARBOCAINE Solution for injection MPI, US: SPL/Old FDA, National Drug Code (US)
 CATHEJELL Jelly in collapsible syringe MPI, CA: SPM Health Products and Food Branch (CA)
 CHIROCAINE Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 CITANEST PLAIN Solution for injection MPI, US: SPL/Old FDA, National Drug Code (US)
 EXPAREL Suspension for solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 INSTILLAGEL Gel MPI, EU: SmPC Υπουργείο Υγείας (CY)
 LIDBREE Intrauterine gel MPI, EU: SmPC Health Products Regulatory Authority (IE)
 MARCAIN HEAVY Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 MARCAIN POLYAMP STERIPACK Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 MARCAINE Solution for injection MPI, US: SPL/Old FDA, National Drug Code (US)
 NAROPIN Solution for injection MPI, US: SPL/Old FDA, National Drug Code (US)
 PRILOTEKAL Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 ROPIVACAINE Solution for infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 SCANDONEST 3% PLAIN Solution for injection MPI, EU: SmPC
 SENSORCAINE Solution for injection MPI, US: SPL/Old FDA, National Drug Code (US)
 XYLOCAINE Spray MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 ZINGO Powder intradermal injection MPI, US: SPL/PLR FDA, National Drug Code (US)